Anti-TNF-α Therapy on Bone Mineral Density in Patients with Inflammatory Bowel Disease: An Expanded Cross-sectional Analysis
Shiraz E-Medical Journal · 05.05.2026 · 27 (4)
DOI: 10.5812/semj-168706 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Shiraz E-Medical Journal, online erschienen am 05.05.2026. Verfasst von Zahra Shokati Eshkiki und 3 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Patients with inflammatory bowel disease (IBD) experience a disproportionately high burden of low bone mineral density (BMD) and osteoporosis compared with the general population. Chronic inflammation, nutritional deficiencies, corticosteroid exposure, and changes in body composition all contribute to impaired bone health.
Objectives
We aimed to investigate the bone metabolism in cases with anti-tumor necrosis factor-alpha (anti-TNF-α) agents which are widely used to control moderate-to-severe IBD. We examinedd the association between anti-TNF-α therapy and BMD in a cohort of IBD patients receiving care at a tertiary center.
Methods
This cross-sectional study enrolled 58 patients with ulcerative colitis or Crohn’s disease were enrolled (29 receiving anti-TNF-α and 29 receiving azathioprine-based therapy). Clinical history, medication exposure, cumulative corticosteroid dose, nutritional supplementation, vitamin D levels, disease activity, and lifestyle factors were recorded. Dual-energy X-ray absorptiometry (DEXA) was used to measure lumbar and femoral BMD. Multivariable logistic regression was performed to identify independent predictors of osteoporosis. Resultss: Overall, 43.1% of participants met criteria for osteoporosis based on Z-scores, with markedly higher prevalence among anti-TNF-α users (65.5% vs. 20.7%, P = 0.01). After adjusting for confounders, anti-TNF-α therapy (OR 3.50; 95% CI 1.20 - 10.20), lower BMD (OR 2.00; 95% CI 1.10 - 3.60), higher cumulative corticosteroid exposure (OR 1.50; 95% CI 1.10 - 2.00), and lower BMI (OR 1.20; 95% CI 1.05 - 1.40) were independently associated with osteoporosis.
Conclusions
These findings demonstrate a significant association between anti-TNF-α therapy and lower bone mineral density in patients with inflammatory bowel disease. Given the cross-sectional design, causal relationships cannot be established, and residual confounding by disease severity and treatment indication remains likely. Larger prospective and longitudinal studies are required to clarify the temporal and mechanistic relationships between anti-TNF-α therapy and bone metabolism.
Zitieren
APA
Eshkiki, Z. S., Akbari, A., Eghbalmanesh, M., & Pishgar, E. (2026). Anti-TNF-α Therapy on Bone Mineral Density in Patients with Inflammatory Bowel Disease: An Expanded Cross-sectional Analysis. Shiraz E-Medical Journal, 27(4). https://doi.org/10.5812/semj-168706
Vancouver
Eshkiki ZS, Akbari A, Eghbalmanesh M, Pishgar E. Anti-TNF-α Therapy on Bone Mineral Density in Patients with Inflammatory Bowel Disease: An Expanded Cross-sectional Analysis. Shiraz E-Medical Journal. 2026;27(4). doi:10.5812/semj-168706
BibTeX
@article{Eshkiki2026,
author = {Eshkiki, Zahra Shokati and Akbari, Abolfazl and Eghbalmanesh, Mahshad and Pishgar, Elham},
title = {Anti-TNF-α Therapy on Bone Mineral Density in Patients with Inflammatory Bowel Disease: An Expanded Cross-sectional Analysis},
journal = {Shiraz E-Medical Journal},
year = {2026},
volume = {27},
number = {4},
doi = {10.5812/semj-168706}
}
EUVIMED